ArticleBlood advances2021

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.

Jonathan C Strefford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.